CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
暂无分享,去创建一个
Eric P Tamm | Haesun Choi | D. Podoloff | Haesun Choi | R. Benjamin | H. Macapinlac | C. Charnsangavej | E. Tamm | Robert S Benjamin | Marcella M Johnson | Marcella M. Johnson | Homer A Macapinlac | Chuslip Charnsangavej | Donald A Podoloff | Silvana de Castro Faria | S. de Castro Faria | Silvana de Castro Faria
[1] S. Hirota,et al. Biological and clinical review of stromal tumors in the gastrointestinal tract. , 2000, Histology and histopathology.
[2] C. Muro-Cacho,et al. Gastrointestinal stromal tumors. , 2001, Cancer control : journal of the Moffitt Cancer Center.
[3] P. Marsden,et al. Principles and technology of PET scanning. , 2000, Nuclear medicine communications.
[4] J. Fletcher,et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.
[5] D Delbeke,et al. Oncological applications of FDG PET imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] E. Pauwels,et al. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology , 2001, Journal of Cancer Research and Clinical Oncology.
[7] M. O'Doherty. PET in oncology I--lung, breast, soft tissue sarcoma. , 2000, Nuclear medicine communications.
[8] B. Druker,et al. STI571: a paradigm of new agents for cancer therapeutics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[10] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.
[11] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[12] J. Folkman. Tumor angiogenesis and tissue factor , 1996, Nature Medicine.
[13] B. Druker,et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[14] International criteria for measurement of tumour response , 2001, Cancer Imaging.
[15] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[16] L. Ackerman,et al. Ackerman's surgical pathology , 1974 .
[17] P. Choyke,et al. Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.
[18] S. Reske,et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? , 1999, European Journal of Nuclear Medicine.
[19] William E. Neville,et al. Gastrointestinal Tract , 1959 .
[20] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.